(Circulation. 2000;101:118.)
© 2000 American Heart Association, Inc.
Brief Rapid Communications |
Effect of Intracoronary Recombinant Human Vascular Endothelial Growth Factor on Myocardial Perfusion
Evidence for a Dose-Dependent Effect
From Northwestern University Medical School, Chicago, Ill (R.C.H., R.O.B.); Hennepin County Medical Center, Minneapolis, Minn (T.D.H.); Prairie Cardiovascular Consultants, Springfield, Ill (K.R.-S.); St Elizabeth’s Medical Center, Boston, Mass (J.M.I.); Lindner Center for Clinical Cardiovascular Research, Cincinnati, Ohio (D.J.K.); Yale University School of Medicine, New Haven, Conn (F.J.G.); and Beth Israel Deaconess Medical Center, Boston, Mass (M.S.).
Correspondence to Robert C. Hendel, MD, 1725 W Harrison St, Chicago, IL 60612-3864. E-mail rhendel{at}rush.edu
Background—Animal models of therapeutic angiogenesis have stimulated development of clinical application in patients with limited options for coronary revascularization. The impact of recombinant human vascular endothelial growth factor (rhVEGF) on myocardial perfusion in humans has not been reported.
Methods and Results—Fourteen patients underwent exercise (n=11), dobutamine (n=2), or dipyridamole (n=1) myocardial perfusion single photon emission CT (SPECT) before as well as 30 and 60 days after rhVEGF administration. After uniform processing and display, 2 observers blinded to the timing of the study and dose of rhVEGF reviewed the SPECT images. By a visual, semiquantitative 20-segment scoring method, summed stress scores (SSS) and summed rest scores (SRS) were generated. Although the SSS did not change from baseline to 30 days (21.6 versus 21.5; P=NS), the SRS improved after rhVEGF (13.2 versus 10.4; P<0.05). Stress and rest perfusion improved in >2 segments infrequently in patients treated with low-dose rhVEGF. However, 5 of 6 patients had improvement in >2 segments at rest and stress with the higher rhVEGF doses. Furthermore, although neither the SSS nor the SRS changed in patients treated with the low doses, the SRS decreased in the high-dose rhVEGF patients at 60 days (14.7 versus 10.7; P<0.05). Quantitative analysis was consistent with the visual findings but failed to demonstrate statistical significance.
Conclusions—Although not designed to demonstrate rhVEGF efficacy, these phase 1 data support the concept that rhVEGF improves myocardial perfusion at rest and provide evidence of a dose-dependent effect.
Key Words: growth substances • tomography • angiogenesis
This article has been cited by other articles:
 |
|
 |
|
  K. A. Horvath and Y. Zhou Transmyocardial Laser Revascularization and Extravascular Angiogenetic Techniques to Increase Myocardial Blood Flow Card. Surg. Adult, January 1, 2008; 3(2008): 733 - 752. [Full Text]
|
|
|
|
 |
|
 H. Lu, X. Xu, M. Zhang, R. Cao, E. Brakenhielm, C. Li, H. Lin, G. Yao, H. Sun, L. Qi, et al. Combinatorial protein therapy of angiogenic and arteriogenic factors remarkably improves collaterogenesis and cardiac function in pigs PNAS, July 17, 2007; 104(29): 12140 - 12145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yla-Herttuala, T. T. Rissanen, I. Vajanto, and J. Hartikainen Vascular Endothelial Growth Factors: Biology and Current Status of Clinical Applications in Cardiovascular Medicine J. Am. Coll. Cardiol., March 13, 2007; 49(10): 1015 - 1026. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ishikawa, M. Eguchi, M. Wada, Y. Iwami, K. Tono, H. Iwaguro, H. Masuda, T. Tamaki, and T. Asahara Establishment of a Functionally Active Collagen-Binding Vascular Endothelial Growth Factor Fusion Protein In Situ Arterioscler. Thromb. Vasc. Biol., September 1, 2006; 26(9): 1998 - 2004. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Stritesky, M. Dobias, R. Demes, M. Semrad, E. Poliachova, T. Cermak, J. Charvat, and I. Malek Endoscopic thoracic sympathectomy - its effect in the treatment of refractory angina pectoris Interactive CardioVascular and Thoracic Surgery, August 1, 2006; 5(4): 464 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. U. Lee, J. J. Wykrzykowska, and R. J. Laham Angiogenesis: Bench to Bedside, Have We Learned Anything? Toxicol Pathol, January 1, 2006; 34(1): 3 - 10. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hanif, A. Patel, and J. Dunning Might gene therapy offer symptomatic relief for patients with 'no option' angina? Interactive CardioVascular and Thoracic Surgery, December 1, 2005; 4(6): 627 - 632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Toyota, D. C. Warltier, T. Brock, E. Ritman, C. Kolz, P. O'Malley, P. Rocic, M. Focardi, and W. M. Chilian Vascular Endothelial Growth Factor Is Required for Coronary Collateral Growth in the Rat Circulation, October 4, 2005; 112(14): 2108 - 2113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gyongyosi, A. Khorsand, S. Zamini, W. Sperker, C. Strehblow, J. Kastrup, E. Jorgensen, B. Hesse, K. Tagil, H. E. Botker, et al. NOGA-Guided Analysis of Regional Myocardial Perfusion Abnormalities Treated With Intramyocardial Injections of Plasmid Encoding Vascular Endothelial Growth Factor A-165 in Patients With Chronic Myocardial Ischemia: Subanalysis of the EUROINJECT-ONE Multicenter Double-Blind Randomized Study Circulation, August 30, 2005; 112(9_suppl): I-157 - I-165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J Teng, K. Lachapelle, and R. C. Chiu Reappraisal of Recent Clinical Trials of Angiogenic Therapy in Myocardial Ischemia Asian Cardiovasc Thorac Ann, March 1, 2005; 13(1): 90 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. H. Annex and M. Simons Growth factor-induced therapeutic angiogenesis in the heart: protein therapy Cardiovasc Res, February 15, 2005; 65(3): 649 - 655. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wang, E. Kilic, U. Kilic, B. Weber, C. L. Bassetti, H. H. Marti, and D. M. Hermann VEGF overexpression induces post-ischaemic neuroprotection, but facilitates haemodynamic steal phenomena Brain, January 1, 2005; 128(1): 52 - 63. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Slomka, D. S. Berman, and G. Germano Quantification of Serial Changes in Myocardial Perfusion J. Nucl. Med., December 1, 2004; 45(12): 1978 - 1980. [Full Text] [PDF]
|
|
|
|
 |
|
 E. R. Schwarz, D. A. Meven, N. Z. Sulemanjee, P. H. Kersting, T. Tussing, E. C. Skobel, P. Hanrath, and B. F. Uretsky Monocyte Chemoattractant Protein 1-Induced Monocyte Infiltration Produces Angiogenesis but Not Arteriogenesis in Chronically Infarcted Myocardium Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2004; 9(4): 279 - 289. [Abstract] [PDF]
|
|
|
|
|
|
P. Raake, G. von Degenfeld, R. Hinkel, R. Vachenauer, T. Sandner, S. Beller, M. Andrees, C. Kupatt, G. Schuler, and P. Boekstegers Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins: Comparison with surgical and percutaneous intramyocardial gene delivery J. Am. Coll. Cardiol., September 1, 2004; 44(5): 1124 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. van Weel, M. M.L. Deckers, J. M. Grimbergen, K. J.M. van Leuven, J. H.P. Lardenoye, R. O. Schlingemann, G. P. van Nieuw Amerongen, J. H. van Bockel, V. W.M. van Hinsbergh, and P. H.A. Quax Vascular Endothelial Growth Factor Overexpression in Ischemic Skeletal Muscle Enhances Myoglobin Expression In Vivo Circ. Res., July 9, 2004; 95(1): 58 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. K. Lund, A. Stork, M. Saeed, M. P. Bansmann, J. H. Gerken, V. Muller, J. Mester, C. B. Higgins, G. Adam, and T. Meinertz Acute Myocardial Infarction: Evaluation with First-Pass Enhancement and Delayed Enhancement MR Imaging Compared with 201Tl SPECT Imaging Radiology, July 1, 2004; 232(1): 49 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Friehs, A. M. Moran, C. Stamm, Y.-H. Choi, D. B. Cowan, F. X. McGowan, and P. J. del Nido Promoting angiogenesis protects severely hypertrophied hearts from ischemic injury Ann. Thorac. Surg., June 1, 2004; 77(6): 2004 - 2010. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Ye, H. K Haider, S.-J. Jiang, and E. K. Sim Therapeutic Angiogenesis Using Vascular Endothelial Growth Factor Asian Cardiovasc Thorac Ann, June 1, 2004; 12(2): 173 - 181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Losordo and S. Dimmeler Therapeutic Angiogenesis and Vasculogenesis for Ischemic Disease: Part I: Angiogenic Cytokines Circulation, June 1, 2004; 109(21): 2487 - 2491. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Schalch, G. F. Rahman, G. Patejunas, R. A. Goldschmidt, J. Carbray, M. A. Retuerto, D. Kim, K. Esser, R. G. Crystal, and T. K. Rosengart Adenoviral-mediated transfer of vascular endothelial growth factor 121 cDNA enhances myocardial perfusion and exercise performance in the nonischemic state J. Thorac. Cardiovasc. Surg., February 1, 2004; 127(2): 535 - 540. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Grines, M. W. Watkins, J. J. Mahmarian, A. E. Iskandrian, J. J. Rade, P. Marrott, C. Pratt, N. Kleiman, and for the Angiogenic GENe Therapy (AGENT-2) Study Gr A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina J. Am. Coll. Cardiol., October 15, 2003; 42(8): 1339 - 1347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Fuchs, L. F. Satler, R. Kornowski, P. Okubagzi, G. Weisz, R. Baffour, R. Waksman, N. J. Weissman, M. Cerqueira, M. B. Leon, et al. Catheter-based autologous bone marrow myocardial injection in no-option patients with advanced coronary artery disease: A feasibility study J. Am. Coll. Cardiol., May 21, 2003; 41(10): 1721 - 1724. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Lenihan, A. Osman, V. Sriram, J. Aitsebaomo, and C. Patterson Evidence for association of coronary sinus levels of hepatocyte growth factor and collateralization in human coronary disease Am J Physiol Heart Circ Physiol, May 1, 2003; 284(5): H1507 - H1512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. D. Henry, B. H. Annex, G. R. McKendall, M. A. Azrin, J. J. Lopez, F. J. Giordano, P.K. Shah, J. T. Willerson, R. L. Benza, D. S. Berman, et al. The VIVA Trial: Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis Circulation, March 18, 2003; 107(10): 1359 - 1365. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Friehs and P. J. del Nido Increased susceptibility of hypertrophied hearts to ischemic injury Ann. Thorac. Surg., February 1, 2003; 75(2): S678 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. L. DeJongste, R. W. M. Hautvast, and R. A. Tio Therapeutic options for patients with chronic refractory angina pectoris J. Am. Coll. Cardiol., October 16, 2002; 40(8): 1541 - 1541. [Full Text] [PDF]
|
|
|
|
|
|
E. Leotta, G. Patejunas, G. Murphy, J. Szokol, L. McGregor, J. Carbray, A. Hamawy, D. Winchester, N. Hackett, R. Crystal, et al. Gene therapy with adenovirus-mediated myocardial transfer of vascular endothelial growth factor 121 improves cardiac performance in a pacing model of congestive heart failure J. Thorac. Cardiovasc. Surg., June 1, 2002; 123(6): 1101 - 1113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. L. Bale, F. J. Giordano, R. P. Hickey, Y. Huang, A. K. Nath, K. L. Peterson, W. W. Vale, and K.-F. Lee Corticotropin-releasing factor receptor 2 is a tonic suppressor of vascularization PNAS, May 28, 2002; 99(11): 7734 - 7739. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Freedman and J. M. Isner Therapeutic Angiogenesis for Coronary Artery Disease Ann Intern Med, January 1, 2002; 136(1): 54 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Seiler, T. Pohl, K. Wustmann, D. Hutter, P.-A. Nicolet, S. Windecker, F. R. Eberli, and B. Meier Promotion of Collateral Growth by Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Coronary Artery Disease: A Randomized, Double-Blind, Placebo-Controlled Study Circulation, October 23, 2001; 104(17): 2012 - 2017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Azrin Angiogenesis, protein and gene delivery Br. Med. Bull., October 1, 2001; 59(1): 211 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Schwaiger Future perspectives and conclusions Eur. Heart J. Suppl., September 1, 2001; 3(suppl_F): F19 - F21. [Abstract] [PDF]
|
|
|
|
 |
|
 J. M. Abrahams, M. S. Forman, M. Sean Grady, and S. L. Diamond Delivery of Human Vascular Endothelial Growth Factor with Platinum Coils Enhances Wall Thickening and Coil Impregnation in a Rat Aneurysm Model AJNR Am. J. Neuroradiol., August 1, 2001; 22(7): 1410 - 1417. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. N. Oesterle, N. Reifart, E. Hauptmann, M. Hayase, and A. C. Yeung Percutaneous In Situ Coronary Venous Arterialization : Report of the First Human Catheter-Based Coronary Artery Bypass Circulation, May 29, 2001; 103(21): 2539 - 2543. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Giordano, H.-P. Gerber, S.-P. Williams, N. VanBruggen, S. Bunting, P. Ruiz-Lozano, Y. Gu, A. K. Nath, Y. Huang, R. Hickey, et al. A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function PNAS, April 25, 2001; (2001) 91415198. [Abstract] [Full Text]
|
|
|
|
|
|
L. M. Goncalves, S. E. Epstein, and J. J. Piek Controlling collateral development: the difficult task of mimicking mother nature Cardiovasc Res, February 16, 2001; 49(3): 495 - 496. [Full Text] [PDF]
|
|
|
|
|
|
M. J. Post, R. Laham, F. W. Sellke, and M. Simons Therapeutic angiogenesis in cardiology using protein formulations Cardiovasc Res, February 16, 2001; 49(3): 522 - 531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Epstein, S. Fuchs, Y. F. Zhou, R. Baffour, and R. Kornowski Therapeutic interventions for enhancing collateral development by administration of growth factors: basic principles, early results and potential hazards Cardiovasc Res, February 16, 2001; 49(3): 532 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. van Royen, J. J. Piek, I. Buschmann, I. Hoefer, M. Voskuil, and W. Schaper Stimulation of arteriogenesis; a new concept for the treatment of arterial occlusive disease Cardiovasc Res, February 16, 2001; 49(3): 543 - 553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Lefkowitz and J. T. Willerson Prospects for Cardiovascular Research JAMA, February 7, 2001; 285(5): 581 - 587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Abraham, R. Hofbauer, R. Schafer, R. Blumer, P. Paulus, A. Miksovsky, H. Traxler, A. Kocher, and S. Aharinejad Selective Downregulation of VEGF-A165, VEGF-R1, and Decreased Capillary Density in Patients With Dilative but Not Ischemic Cardiomyopathy Circ. Res., October 13, 2000; 87(8): 644 - 647. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Udelson, V. Dilsizian, R. J. Laham, N. Chronos, J. Vansant, M. Blais, J. R. Galt, M. Pike, C. Yoshizawa, and M. Simons Therapeutic Angiogenesis With Recombinant Fibroblast Growth Factor-2 Improves Stress and Rest Myocardial Perfusion Abnormalities in Patients With Severe Symptomatic Chronic Coronary Artery Disease Circulation, October 3, 2000; 102(14): 1605 - 1610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Pantely and J. M. Porter Therapeutic angiogenesis: time for the next phase J. Am. Coll. Cardiol., October 1, 2000; 36(4): 1245 - 1247. [Full Text] [PDF]
|
|
|
|
|
|
M. Simons, R. O. Bonow, N. A. Chronos, D. J. Cohen, F. J. Giordano, H. K. Hammond, R. J. Laham, W. Li, M. Pike, F. W. Sellke, et al. Clinical Trials in Coronary Angiogenesis: Issues, Problems, Consensus : An Expert Panel Summary Circulation, September 12, 2000; 102 (11): e73 - e86. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Lee, M. L. Springer, W. E. Blanco-Bose, R. Shaw, P. C. Ursell, and H. M. Blau VEGF Gene Delivery to Myocardium : Deleterious Effects of Unregulated Expression Circulation, August 22, 2000; 102(8): 898 - 901. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Therapeutic Angiogenesis: Is It for Real? Journal Watch Cardiology, February 18, 2000; 2000(218): 3 - 3. [Full Text]
|
|
|
|
 |
|
 M. Donovan, M. Lin, P Wiegn, T Ringstedt, R Kraemer, R Hahn, S Wang, C. Ibanez, S Rafii, and B. Hempstead Brain derived neurotrophic factor is an endothelial cell survival factor required for intramyocardial vessel stabilization Development, January 11, 2000; 127(21): 4531 - 4540. [Abstract] [PDF]
|
|
|
|
 |
|
 P.-Q. Liu, E. J. Rebar, L. Zhang, Q. Liu, A. C. Jamieson, Y. Liang, H. Qi, P.-X. Li, B. Chen, M. C. Mendel, et al. Regulation of an Endogenous Locus Using a Panel of Designed Zinc Finger Proteins Targeted to Accessible Chromatin Regions. ACTIVATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR A J. Biol. Chem., March 30, 2001; 276(14): 11323 - 11334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Giordano, H.-P. Gerber, S.-P. Williams, N. VanBruggen, S. Bunting, P. Ruiz-Lozano, Y. Gu, A. K. Nath, Y. Huang, R. Hickey, et al. A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function PNAS, May 8, 2001; 98(10): 5780 - 5785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. S. Villanueva, J. A. Abraham, G. F. Schreiner, M. Csikari, D. Fischer, J. D. Mills, U. Schellenberger, B. J. Koci, and J. S. Lee Myocardial Contrast Echocardiography Can Be Used to Assess the Microvascular Response to Vascular Endothelial Growth Factor-121 Circulation, February 12, 2002; 105(6): 759 - 765. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Simons, B. H. Annex, R. J. Laham, N. Kleiman, T. Henry, H. Dauerman, J. E. Udelson, E. V. Gervino, M. Pike, M.J. Whitehouse, et al. Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2: Double-Blind, Randomized, Controlled Clinical Trial Circulation, February 19, 2002; 105(7): 788 - 793. [Abstract] [Full Text] [PDF]
|
|